Abstract

Sodium glucose co-transporter 2 inhibitors (SGLT2i) are a new class of oral antidiabetic agents that is considered a breakthrough in the history of management of diabetes due to the famous cardiovascular outcome trials [1]. These agents lower blood glucose by inhibition of the reabsorption of filtered glucose at the proximal convoluted tubule in the kidneys. Thus, glycosuria will result which will lead to loss of calories and consequently weight loss. Because these agents act in a non-insulin dependent fashion, several imminent diabetologists have suggested the potential possible benefit of using these agents as adjunct to insulin in patients with type 1 diabetes (T1D). However, the Food and Drug Administration (FDA) has recently disapproved the use of one of these agents, sotagliflozin, in T1D.